At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Active-controlled, Observer-blind Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults Who Previously Received a Complete Primary Vaccination Series With or Without Booster Dose(s)
In Brief
A Phase 2 clinical trial evaluating CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), and 4 other interventions for SARS-CoV-2 and COVID-19. Completed, enrolled 692 participants across 17 sites in 2 countries.
Detailed Summary
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.
Study Details
Timeline
Interventions
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.